Review Article
A Revolutionary Blueprint for Mitigation of Hypertension via Nanoemulsion

Girish Kumar,1 Tarun Virmani,1 Kamla Pathak,2 and Abdulsalam Alhalmi

1School of Pharmaceutical Sciences, MVN University, Haryana 121105, India
2Uttar Pradesh University of Medical Sciences, Etawah, Uttar Pradesh 206001, India
3Department of Pharmaceutics, College of Pharmacy, Aden University, Aden, Yemen

Correspondence should be addressed to Kamla Pathak; kamlapathak5@mvn.edu.in

Received 26 November 2021; Accepted 5 April 2022; Published 14 April 2022

Copyright © 2022 Girish Kumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hypertension is one of the most important causes of mortality, affecting the health status of the patient. At the same time, hypertension causes a huge health and economic burden on the whole world. The incidence and prevalence of hypertension are rising even among young people in both urban as well as rural communities. Although various conventional therapeutic moieties are available for the management of hypertension, they have serious flaws such as hepatic metabolism, reduced dose frequency, poor aqueous solubility, reduced bioavailability, and increased adverse effects, making the drug therapy ineffective. Therefore, it is required to design a novel drug delivery system having the capability to solve the constraints associated with conventional treatment of hypertension. Nanotechnology is a new way of using and manipulating the matter at the molecular level, whose functional organization is measured in nanometers. The applications of nanotechnology in the field of medicine provide an alternative and novel direction for the treatment of cardiovascular diseases and show excellent performance in the field of targeted drug therapy. Various nanotechnologies based drug delivery systems, such as solid lipid nanoparticles, nanosuspension, nanoemulsion, liposome, self-emulsifying systems, and polymeric nanoparticles, are available. Among them, nanoemulsion has provided a niche to supplement currently available therapeutic choices due to numerous benefits like stability, ease of preparation, enhanced drug absorption, reduced hepatic metabolism, increased dose frequency, enhanced bioavailability, and encapsulation of hydrophilic as well as hydrophobic drugs. This present review provides an in-depth idea about progression in treatment of hypertension, constraints for antihypertensive drug therapy, need of nanoemulsions to overcome these constraints, comparative analysis of nanoemulsions over other nanostructure drug delivery systems, pharmacodynamics studies of nanoemulsions for treatment of hypertension, recent patents for drug-loaded nanoemulsions meant for hypertension, and marketed formulations of nanoemulsions for hypertension.

1. Introduction
Hypertension is a severe medical condition that raises the threat of brain, heart, and kidney disorders dramatically specified by the perpetual high pressure in the blood vessels [1]. The systolic BP (the pressure exerted by the arterial walls upon the contraction of the heart) to the diastolic BP (the pressure exerted on the arterial walls upon the relaxation of the heart) ratio is a typical way to express blood pressure [2]. It is a serious public health concern and one of the leading causes of death globally. According to World Health Organization, approximately 1.3 billion people globally are affected by hypertension, with the majority (two-thirds) residing in low- and middle-income nations. In a survey conducted in the year 2015, it was shown that one in four women and one in five men are suffering from the problem of hypertension. It was estimated that only about one in every five patients with hypertension has their condition under control, and about 9 million deaths globally are attributed to hypertension globally. The worldwide noncommunicable disease target is to reduce the pervasiveness of hypertension by 25% between 2010 and 2025 [3]. A variety of conventional therapeutic agents acting through various mechanisms are available for the treatment of hypertension.
but suffers from various constraints like poor aqueous solubility, reduced bioavailability, hepatic metabolism, dose frequency, lack of organ targeting, and higher adverse effects, which can be defeated by the development of advanced systems for drug delivery [4, 5]. Advanced drug delivery systems involve the development of a nanotechnological technique, which is a rapidly developing sophisticated scientific field that encompasses a wide range of disciplines such as chemistry, physics, and biology, as well as unique nanodimension structures with therapeutic applications in pharmacology and the biomedical field [6–8]. Many researchers and scientists are interested in the development and standardization of nanoscale drug delivery systems for a variety of reasons. The nanodimension has a variety of features, including optical, magnetic, and structural surface area ratios, making it a fascinating topic of research in every aspect. It is used as a nanocarrier and a nanoadsorbent and functions as a nanocarrier of therapeutic agents, proteins, or probes, especially because the surface area of nanoscale therapeutics or devices is high [9–11]. These nanoscale approaches include solid lipid nanoparticles, nanoemulsion, nanosuspension, nanoparticles, liposomes, and self-emulsifying systems, among nanoemulsion seems to be a promising and exciting approach to address the constraints of conventional treatment employed for hypertension. Nanoemulsions are ideal drug delivery carriers as they have the potential to dissolve a large amount of lipophilic drugs, have higher compatibility, ability to shield drugs from hydrolysis and enzymatic degradation, and highly effective transportation system because of their extreme micro droplet size with large surface area. They are superior to microemulsions as they avoid the problems associated with microemulsions like coalescence, flocculation, or inherent creaming. Due to various advantages, nanoemulsion drug delivery systems are used in a variety of dosage forms (creams, sprays, foams, solutions, etc.) and result in widespread adoption of them in the pharmaceutical business [12–17]. The current article considers the constraints associated with conventional antihypertensive therapeutics, as well as the significance of the oral nanoemulsion drug delivery method in overcoming the constraints and improving hypertension treatment.

2. Hypertension

Hypertension is one of the most important public health issues, widely acknowledged as the leading cause of global illness burden. It is a lifestyle illness that can be effectively treated by combining a healthy diet with frequent physical activity and maintaining a healthy weight [18]. It is a silent killer because no symptoms are visible in the early stages until a serious medical crisis such as a heart attack, stroke, or chronic renal failure occurs [19]. Because the majority of people are unaware of high blood pressure, the only way to detect it is through measurement. Although the majority of people suffering from hypertension are asymptomatic, some suffer from vertigo, headache, vision alteration, or fainting episodes [20, 21]. A combination of various factors persuading to hypertension and these factors fluctuate from country to country, and even within a country, there are differences between urban and rural communities [22]. When compared to their rural counterparts, city dwellers are more susceptible to certain ailments. According to the National Family Health Survey, India, the prevalence of hypertension was 10.5% in Uttar Pradesh’s metropolitan areas and the prevalence of the same issue was 8.3% in rural areas, indicating the higher prevalence of hypertension in urban areas than in rural areas. Quick urbanization, an ageing population, mechanization, changing lifestyles, and dietary changes all contribute to a web of risk factors that entangles people leading to hypertension [20]. The vessels transport blood from the heart to all regions of the body. The heart pumps blood into the veins every time it beats. The force of blood pushing against the walls of blood vessels (arteries) as it is pumped by the heart causes blood pressure [23, 24]. The higher the pressure, the more difficult it is for the heart to pump causing hypertension as depicted using Figures 1(a) and 1(b), and the mechanism responsible for an increase in blood pressure causing hypertension is represented by Figure 2. The normal blood pressure is 120 mmHg (systolic pressure) and 80 mmHg (diastolic pressure), and beyond it, the condition of hypertension raised [25]. The management of hypertension is primarily linked to a reduction in modifiable risk factors and treatment [18].

2.1. Progression in Drug Treatment for Hypertension.

Various drug molecules having different mechanisms are available for the treatment of hypertension. Pentaquine was the first drug molecule produced to treat hypertension in 1946; however, it had several side effects and had limited therapeutic efficacy. After this, hexamethonium was introduced in the early 1950s, and while it was effective, it was inconvenient to use [4]. When Veratrum was introduced, it was highly toxic, along with the quick onset of action [26]. Hydralazine was developed immediately after the negative effects of ganglionic blockers, and it is now rarely recommended. Because of its negative effects, such as depression and impotency, reserpine, the most successful medicine developed at the time, was also abandoned [27]. The contemporary age of hypertension therapy began in 1960 with breakthrough medications such as diuretics and β-blockers, which are now frequently prescribed. Drugs blocking calcium channels, inhibiting angiotensin-converting enzymes, and blocking angiotensin were originally developed in the 1990s and are now utilized as first-line therapy, either alone or in combination. The development of various newer drugs for hypertension has been aided by a rigorous consideration of the renin angiotensinogen aldosterone system. There has been significant progress in the development of innovative treatments, one of which has a target that is also related to the renin angiotensinogen aldosterone system [28, 29]. The unique targets that have opened up new avenues for the effective development of antihypertensive now in the preclinical and clinical stages of development are depicted in Figure 3.

2.2. Constraints Associated with Antihypertensive Drugs.

In general, a drug’s solubility and its permeability are critical parameters contributing to the oral absorption of the drugs. For a drug to exhibit higher oral absorption, both its solubility and its permeability must be higher. The drugs belonging
Figure 1: (a) Normal blood flow through a blood vessel and (b) obstruction in blood flow through a blood vessel leading to hypertension.

Figure 2: A schematic representation of various processes involved in increasing blood pressure.

Figure 3: Novel targets for antihypertensive drugs.
to BCS class II exhibit poor aqueous solubility, contributing to the low bioavailability of the drugs [30, 31]. The majority of the antihypertensive drug molecules have poor aqueous solubility, leading to low bioavailability [13, 32]. Various antihypertensive drugs having poor bioavailability are summarized in Table 1, showing the class of drug, its aqueous solubility, permeability, and bioavailability, illustrating that poor aqueous solubility acts as the main constraint in oral absorption of the drugs attributing to low bioavailability.

### Table 1: Drugs used in the treatment of hypertension along with their characteristics.

| Class                     | Drug            | Aqueous solubility | Permeability (log P) | Bioavailability | Ref. |
|---------------------------|-----------------|--------------------|----------------------|-----------------|------|
| Calcium channel blockers  | Verapamil       | 7 mg/ml            | 3.8                  | 10-20%          | [33] |
|                           | Felodipine      | 7.15 µg/ml         | 4.36                 | 15%             | [34] |
|                           | Nisoldipine     | 5.7 µg/ml          | 3.1                  | Less than 5%    | [35] |
| AT1 receptor antagonist   | Irbesartan      | Less than 1 mg/ml  | 4.5                  | 60-80%          | [41] |
|                           | Telmisartan     | 0.09 mg/ml         | 7.7                  | 42%             | [42] |
|                           | Olmesartan      | 7.42 µg/ml         | 3.97                 | 26%             | [43] |
|                           | Atenolol        | 1.33 mg/ml         | 0.16                 | 50-60%          | [44] |
|                           | Metoprolol      | 50 mg/ml           | 2.15                 | 50%             | [45] |
| β-Blockers                | Acebutolol      | 200 mg/ml          | 1.53                 | 40%             | [46] |
|                           | Carvedilol      | 0.583 µg/ml        | 4.1                  | 23%             | [47] |
| Renin inhibitor           | Remikiren       | 0.0213 mg/ml       | 3.9                  | 2.5%            | [48] |
|                           | Aliskiren       | 122 mg/ml          | 2.45                 | 2.5%            | [49] |

3. Nanoemulsion as Drug Delivery System

Nanoemulsion may be defined as an isotropically clear, thermodynamically unstable colloidal dispersion made up of two immiscible phases along with surfactants and cosurfactants to produce a single phase [58]. Every droplet of nanoemulsion exhibits a diameter of 10 to 200 nm which provides various benefits over conventional as well as other modern approaches like an encapsulation of large quantity of the drug, encapsulation of hydrophilic as well as lipophilic drugs, enhanced drug absorption owing to reduced particle size, improved stability, ease of manufacturing, targeting to particular organ or tissue, improved bioavailability, improved aqueous solubility, delivery into several dosage forms, delivery into the body through various routes, substitute for liposomes or another vesicle, improved drug efficacy leading to reduced adverse effects, delivery of peptides prone to enzymatic degradation in GIT, improved drug permeation through the skin, and lack of limitations of macro emulsions like flocculation, creaming, and sedimentation, as represented by Figure 4 [59–64]. Depending on the presence of a disperse phase, the nanoemulsion can be classified into three categories: oil in water (O/W), water in oil (W/O), and multiple emulsion (W/O/W and O/W/O) [65, 66]. Figure 5 depicts the structure and composition of water in oil (W/O) and oil in water (O/W) nanoemulsions, with hydrophilic drugs enclosed within the W/O nanoemulsion and hydrophobic medications encapsulated within the O/W nanoemulsion, resulting in increased bioavailability [67]. The nanoemulsion is composed of the lipid/oil phase, surfactant, and cosurfactant summarized in Table 2 [68, 69].
3.1. Nanoemulsion as Therapeutics in Hypertension.

It is reported that the majority of the antihypertensive drugs have low aqueous solubility, which is attributed to the low bioavailability of the drugs [70]. The advancement in drug delivery systems for antihypertensive drugs is nanotechnology, which will be either nanoparticles or nanoemulsion. The mainstay of the nanoemulsion approach in the management of hypertension is mainly achieved using the oral administration of antihypertensive drugs. Scientists and researchers will be more interested in formulations based on the nanoscale level in the management of hypertension [71, 72]. Since hypertension is associated with various

![Image 1](image1.png)

**Figure 5:** (a) Encapsulation of lipophilic drug in oil-in-water nanoemulsion and (b) encapsulation of hydrophilic drug in water-in-oil nanoemulsion.

| Type of excipients | Examples |
|--------------------|----------|
| Lipid/oil phase    | Soybean oil, coconut oil, sesame oil, cottonseed oil, rice bran oil, Captax 355, safflower oil, Captex 8000, Myritol 318, Witensol, isopropyl myristate, triacetin, Capryol 90, Castor oil, Sefsol-218, rapeseed oil, olive oil, peanut oil, whale oil, shark liver oil, linseed oil, palm kernel oil, corn oil, jojoba oil, citrus seed oil, almond oil, theobroma oil, ethyl palmitate, octamethyltrisiloxane, hexamethyl disiloxane, fatty ester |
| Surfactants         | Labrasil, Cremophor EL, Lauroglycol 90, Tween 80, Tween 60, Tween 20, Span 80, Span 60, Span 40, Span 20, sodium dodecyl sulfate, lecithin, poloxamers, Labrasol |
| Cosurfactant        | ethanol, propylene glycol, n-butanol, isopropyl alcohol, propanol, Carbitol, polyethylene glycol 400, Transcutol |

**Table 2:** Summarized lipid/oil phase, surfactant, and cosurfactant used for nanoemulsion having antihypertensive drugs.
consequences, researchers and formulation scientists are interested in using nanotechnology-based drug delivery systems for consequences associated with hypertension [73]. The administration of nanoemulsion through the oral route is most convenient to deliver the drug than other routes due to various benefits like self-administration, ease to administration, dose accuracy, patient compliance, and cost-effectiveness; primarily, oral administration is preferred [74–76]. In earlier times, various scientists have reported considerable improvement in the oral bioavailability of antihypertensive drugs having poor aqueous solubility and high hydrophobicity using the nanoemulsion technology summarized in Table 3. On administration of poorly aqueous soluble drugs using nanoemulsion, significant improvements in pharmacokinetic parameters (Cmax and AUC) were reported, demonstrating the pharmacokinetic benefit of the nanoemulsion over conventional technology [77–79]. Upon oral ingestion, the nanoemulsions enter the gastrointestinal system (GI tract) and are exposed to a variety of environmental variables [80]. In response, gastric lipase is secreted in the gastrointestinal system due to stimulation of the lipid sensing mechanism, enabling the fractional digestion of the lipid layer of nanoemulsion followed by the yielding of simpler diglycerides, monoglycerides, and free fatty acids [81,82]. The lipase activity is accelerated by the nanoemulsion droplet’s small size. The digestion of the lipid component of the nanoemulsion liberates the drugs, followed by nanoprecipitation [83]. In some cases, the drug will simply partition out of the lipid component into the surrounding aquatic environment. Lipids and lipid digested products in the gastrointestinal tract promote bile production and slow down gastrointestinal motility [84]. Bile components act as endogenous surfactants which promote nanoemulsion solubilization. Thus, bile and preexistent mixed micelles enable the solubilization of freed drug even more and transport it through the unstirred aqueous diffusion layer for absorption [82]. Paracellular or transcellular channels along with M-cells in Peyer’s patches also provide intact absorption of the drugs through the oral route due to endocytosis followed by drug transport into intraepithelial spaces as depicted in Figure 6. Moreover, collisional absorption also happens implying the inadvertent impact absorption of nanoemulsion droplets [85]. Upon absorption, nanoemulsion may enter the systemic circulation through the hepatic portal vein or be interfaced into the perforated lymphatic endothelium [86]. Drugs absorbed through the lymphatic route are delivered directly into the blood circulation, bypassing the hepatic metabolism of the drugs [87]. Thus, various mechanisms interact to provide improvement in the oral bioavailability of drugs having poor aqueous solubility and low bioavailability when administered in the form of nanoemulsion.

**Table 3: Summary of selected oral antihypertensive drug-loaded nanoemulsion.**

| Drug candidate | Oil phase/surfactant/cosurfactant | Method of preparation | Outcomes | Ref. |
|----------------|----------------------------------|----------------------|----------|-----|
| Red ginger     | Coconut oil/Tween 80/PEG 400     | Water titration method | Red ginger provides antihypertensive action by inhibiting ACE | [88] |
| Nisoldipine    | Peceol/Cremophor EL/Transcutol HP | Ultrasonication technique | Improved bioavailability and antihypertensive activity | [89] |
| Nitrendipine   | Capmul MCM, Triacetin/Kolliphor ELP/Transcutol HP | Spontaneous emulsification method | Improvement in penetration of drug | [90] |
| Raspberry ketone | Sefsol 218*/TWEEN 80/Lauroglycol 90 | High energy emulsification technique | Improvement in aqueous solubility and bioavailability | [91] |
| Eplerenone     | Triacetin/Kolliphor EL/Tween 80 | Ultrasonication technique | Improved bioavailability of the drug | [92] |
| Mebudipine     | Ethyl oleate/Tween 80/PEG 400   | Sonication | Improved bioavailability | [93] |
| Olmesartan medoxomil | Soyabean oil 700/Sefsol 218/Solutol HS 15 | Phase inversion technique | Improved pharmacokinetics and therapeutic efficacy of the drug | [94] |
| Ramipril       | Sefsol 218/Tween 80/Carbitol     | Solvent evaporation technique | The improved bioavailability of the drug | [95] |
| Candesartan cilexetil | Soyabean oil/Solutol HS-15/Tween 80 | Spontaneous emulsification | Improved oral absorption of the drug | [96] |
| Valsartan      | Capmul MCM/Labrafil M 2125/Tween 80 | Spontaneous emulsification | The improved oral bioavailability of the drug | [97] |
| Amlodipine besilate | Labrafil M/Tween 80/ethanol | Aqueous phase titration | Relative bioavailability of was 475% than drug suspension | [98] |
| Telmisartan    | Oleic acid/Tween 80/PEG 200     | Ultrasonication technique | Enhanced bioavailability of the drug | [99] |
| Carvedilol     | Peppermint oil/Tween 80/ethanol | Aqueous phase titration | Enhancement in aqueous solubility leading to improved bioavailability | [100] |
| Metoprolol     | Isopropyl myristate/lecithin/isopropyl alcohol | Sonication | Enhanced permeation of the drug through rat skin | [101] |
| Talinolol      | Triacetin/Brij-721/ethanol       | Sonication | Significant improvement in drug release, permeability, and bioavailability | [102] |
3.2. Comparative Analysis of Nanoemulsion versus Another Nanostructured Delivery System. This analysis was carried out by studying research publications published between 2016 and 2021 in the Science Direct, Pubmed, Springer, Taylor & Francis, Google Scholar, and EBSCO databases on nanostructured drug delivery systems to deliver antihypertensive drugs for the management of hypertension. Nanoemulsion for hypertension, novel drug delivery system, advanced drug delivery system, solid lipid nanoparticles for antihypertensive drugs, polymeric micelles for hypertension, nanosuspension to deliver antihypertensive, and self-nanoemulsifying drug delivery system for antihypertensive, and advanced drug delivery system for hypertension were the keywords to study the research publications. Only articles written in English were studied. Articles with possibly relevant titles were then evaluated based on their abstracts, with irrelevant articles being eliminated. After that, all of the publications with potentially relevant abstracts were thoroughly examined. In the meantime, the ones that were not relevant were eliminated. According to an exhaustive study of research publications from 2016 to 2021, nanoemulsion has captured a large market segment in comparison to other nanostructured drug delivery systems for delivering antihypertensive drugs. Figure 7 using a pie chart depicted that nanoemulsion (34%) has a presiding role superseded by solid lipid nanoparticles (29%), self-nanoemulsifying drug delivery systems (27%), nanosuspension (7%), and polymeric micelles (1%) in descending order to deliver the antihypertensive drugs.
Table 4: Summarized patent approval for nanoemulsion for antihypertensive drug.

| Patent number | Therapeutic moiety | Title | Inventor | Outcomes |
|---------------|--------------------|-------|----------|----------|
| CN105997873A  | Terazosin          | Oil-in-water type terazosin nanoemulsion antihypertensive drug | Zhang Hongli | The prolonged half-life of the drug, reduced dose frequency, and improved therapeutic efficacy |
| CN106137958A  | Apigenin           | A kind of compound apigenin nanoemulsion antihypertensive drug | Zhang Hongli | Improved dissolution and penetration power of drug along with an increased instability |
| CN106176997A  | Atenolol           | A kind of compound atenolol nanoemulsion antihypertensive drug | Zhang Hongli | Improved dissolution and penetration power of drug along with an increased instability |
| CN102698245A  | Quinapril          | Antihypertensive drug of quinapril hydrochloride and rose oil nanoemulsion | Ouyang Wuqing, Sun Jianhong, Zhang Xiaohua | The prolonged half-life of the drug, reduced dose frequency, and improved therapeutic efficacy |
| CN102697900A  | Spirolactone       | Compound spirolactone nanoemulsion drug | Ouyang Wuqing, Sun Jianhong, Cao Tong | Improved dissolution and penetration power of drug along with an increased instability |
| CN106137961A  | Celiprolol         | A kind of oil-in-water type celiprolol nanoemulsion antihypertensive drug | Zhang Hongli | Improved stability, prolonged half-life, and enhancement in the therapeutic efficacy of the drug |
| CN106109410A  | Hydralazine        | A kind of hydralazine nanoemulsion antihypertensive drug | Zhang Hongli | The prolonged half-life of the drug, reduced dose frequency, and improved therapeutic efficacy |
| CN105997874A  | Sotalol            | Oil-in-water type sotalol nanoemulsion antihypertensive drug | Zhang Hongli | The prolonged half-life of the drug, reduced dose frequency, and improved therapeutic efficacy |
| CN102716158A  | Mecamylamine       | In-water type mecamylamine and celery seed oil nanoemulsion antihypertensive medicine | Ouyang Wuqing, Sun Jianhong, Gao Qing | Improved antihypertensive activity, the prolonged half-life of the drug along with reduced dose frequency |
| CN106177511A  | Alprenolol         | A kind of compound alprenolol nanoemulsion antihypertensive drug | Zhang Hongli | Improved antihypertensive activity, the prolonged half-life of the drug along with reduced dose frequency |

3.3. Pharmacodynamic Studies of Nanoemulsion Delivering Antihypertensive Drugs. According to a published research by Nada et al., it was found that unilateral ureteral obstruction rats that were given red ginger nanoemulsion had a substantial reduction in systolic blood pressure from 142 ± 1 mmHg to 107 ± 6 mmHg and diastolic blood pressure from 106 ± 1 mmHg to 84 ± 4 mmHg. Additionally, red ginger nanoemulsion therapy resulted in a 10.80% reduction in the level of ACE [88]. In a research study by Mundada et al., it was found that nisoldipine nanoemulsion had a significant reduction in systolic blood pressure from 187.31 ± 18.02 mmHg to 139.68 ± 13.12 mmHg and diastolic blood pressure from 122.36 ± 12.01 mmHg to 101.84 ± 10.28 mmHg [89]. In a research study by Gorain et al., it was observed that systolic blood pressure (115.71 ± 4.800 mmHg) was reduced after 1 hour of administration of Olmesartan nanoemulsion and was controlled up to 12 hours after administration (120.12 ± 5.724 mmHg). The considerable reduction in blood pressure persisted until the 14th day of treatment (108.96 ± 3.24 mmHg at 1 hour and 114.72 ± 3.74 mmHg at 12 hours after administration) until it reached the normal systolic blood pressure [94]. In a study by Chhabra et al., the uptake of amlodipine besilate from the nanoemulsion formulation was higher in almost every organ, especially in the heart than suspension of amlodipine besilate, confirming the targeting activity of nanoemulsion. Percentage uptake of the drug was found to be 11.8 and 13.6 folds greater in the heart at 0.5 hours and 1.0 hours, respectively, from nanoemulsion of amlodipine besilate than suspension of the drug [98].

3.4. Patents for Antihypertensive Nanoemulsion. A patent is the government’s formal right to grant an inventor the sole right to create, sell, or use a product for a specific amount of time [103]. Several patents for nanoemulsion formulations have been issued, demonstrating the widespread acceptance of nanoemulsion formulations [104]. A patent (CN105997873A) was awarded to Zhang Hongli for the preparation of oil-in-water type nanoemulsion containing terazosin as an antihypertensive drug, aiming at prolonging the half-life of the drug, reducing dose frequency, and improving antihypertensive activity of the drug. The patent discloses oil-in-water type nanoemulsion composed of terazosin 1-15%, surfactant 15%-40%, cosurfactant 0-20%, and the remaining amount of distilled water. Ouyang Wuqing et al. granted a patent (CN102698245A) for the preparation of an antihypertensive drug of quinapril hydrochloride and rose oil nanoemulsion aiming at prolonging the half-life of the drug, reducing dose frequency, and improving the...
therapeutic efficacy of the said drug. The patent discloses oil- in-water type nanoemulsion composed of 1-18% of quinapril hydrochloride, 15-40% of surfactant, 0-20% of cosurfactant, and 1-20% of rose oil along with the balanced quantity of distilled water. More supportive data for granted patents in the field of nanoemulsion for antihypertensive drugs has been summarized in Table 4.

4. Conclusions

Nanoemulsion has progressively become the center of research and development these days. In the pharmaceutical industry, nanoemulsion has emerged as a potential and interesting drug delivery technology for cardiovascular diseases. An extensive study has been conducted on a variety of drug delivery systems, which concludes that nanoemulsion has a promising future as a delivery system for antihypertensive drugs. In the coming years, nanoemulsion will become a mainstream practice, with all positive results for the betterment of human society and an increase in life expectancy. Nevertheless, many challenges still need to be overcome to establish their safety and efficacy by performing preclinical and clinical studies. Randomized clinical trials should be performed to gain a better understanding of the effects of various crucial parameters such as droplet size, composition, and charge on the absorption, distribution, and metabolism of the antihypertensive drugs loaded in nanoemulsion. Additionally, various advancements in nanoemulsion like multiple nanoemulsions, in situ nanoemulsion, and self-emulsifying nanoemulsion are yet to be explored for cardiovascular and other diseases.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] A. Barlow, B. Barlow, A. Koyfman, B. Long, and B. Bissell, “Pulmonary arterial hypertension in the emergency department: a focus on medication management,” The American Journal of Emergency Medicine, vol. 47, no. 47, pp. 101–108, 2021.

[2] S. Oparil, M. C. Acclajado, G. L. Bakris et al., “Hypertension,” Nat Rev Dis Prim., vol. 4, no. 1, p. 18014, 2018.

[3] R. Beagles, R. Bonita, M. Ezzati et al., “NCD countdown 2025: accountability for the 25 × 25 NCD mortality reduction target,” Lancet, vol. 384, no. 9938, pp. 105–107, 2014.

[4] T. Alam, S. Khan, B. Gaba, M. F. Haider, S. Baboota, and J. Ali, “Nanoemulsions as treatment modalities for hypertension,” Drug Delivery, vol. 24, no. 1, pp. 358–369, 2017.

[5] D. K. Wang, M. Rahimi, and C. S. Filgueira, “Nanoemulsion applications for cardiovascular disease treatment: current and future perspectives,” Nanomedicine Nanotechnology, Biology Medicine, vol. 1, no. 34, article 102387, 2021.

[6] N. Zahir, R. Anwar, D. Tewari et al., “Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery,” Environmental Science and Pollution Research, vol. 27, no. 16, pp. 19151–19168, 2020.

[7] T. Sahu, Y. K. Ratre, S. Chauhan, L. V. K. S. Bhaskar, M. P. Nair, and H. K. Verma, “Nanotechnology based drug delivery system: current strategies and emerging therapeutic potential for medical science,” Journal of Drug Delivery Science and Technology, vol. 63, no. 63, article 102487, 2021.

[8] A. A. H. Abdellatif, H. A. Mohammed, R. A. Khan et al., “Nano-scale delivery: a comprehensive review of nanostructured devices, preparative techniques, site-specificity designs, biomedical applications, commercial products, and references to safety, cellular uptake, and organ toxicity,” Nanotechnology Reviews, vol. 10, no. 1, pp. 1493–1559, 2021.

[9] J. K. Patra, G. Das, L. F. Fraceto et al., “Nano based drug delivery systems: recent developments and future prospects,” Journal of Nanobiotechnology, vol. 16, no. 1, pp. 1–33, 2018.

[10] S. Naqvi, A. Panghal, and S. J. S. Flora, “Nanotechnology: a promising approach for delivery of neuroprotective drugs,” Frontiers in Neuroscience, vol. 14, no. June, pp. 1–26, 2020.

[11] A. Alhalmi, S. Beg, K. Kohli, M. Waris, and T. Singh, “Nanoemulsion based approach for hepatocellular carcinoma targeting,” Current Drug Targets, vol. 22, no. 7, pp. 779–792, 2021.

[12] A. A. H. Abdellatif and A. F. Alsowinea, “Approved and marketed nanoparticles for disease targeting and applications in COVID-19,” Nanotechnology Reviews, vol. 10, no. 1, pp. 1941–1977, 2021.

[13] M. Sharma, R. Sharma, and D. K. Jain, “Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs,” Scientifica (Cairo), vol. 2016, p. ID 8525679, 2016.

[14] P. Kulkarni, D. Rawtani, M. Kumar, and S. R. Lahoti, “Cardiovascular drug delivery: a review on the recent advancements in nanocarrier based drug delivery with a brief emphasis on the novel use of magnetoliposomes and extracellular vesicles and ongoing clinical trial research,” Journal of Drug Delivery Science and Technology, vol. 1, no. 60, article 102029, 2020.

[15] H. H. Tayeb, R. Felimban, S. Almaghrabi, and N. Hasaballah, “Nanoemulsions: formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks,” Colloids and Interface Science Communications, vol. 45, article 100533, 2021.

[16] M. B. Zewail, S. A. El-Gizawy, M. A. Osman, and Y. A. Haggag, “Preparation and in vitro characterization of a novel self-nano emulsifying drug delivery system for a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide,” Journal of Drug Delivery Science and Technology, vol. 1, no. 61, article 102320, 2021.

[17] M. D. Prajapat, N. J. Patel, A. Bariya, S. S. Patel, and S. B. Butani, “Formulation and evaluation of self-emulsifying drug delivery system for nimodipine, a BC5 class II drug,” Journal of Drug Delivery Science and Technology, vol. 1, no. 39, pp. 59–68, 2017.

[18] D. E. Shumer and NJNNPS, “Prevention and control of hypertension: JACC health promotion series,” Physiology & Behavior, vol. 176, no. 12, pp. 139–148, 2017.

[19] D. L. Joyce, “The invisible silent killer,” Mayo Clinic Proceedings, vol. 96, no. 8, pp. 2022–2024, 2021.

[20] D. Mitsouva-Boneva and X. Wang, “Prevalence and associated risk factors of hypertension: a cross-sectional study in urban Varanasi,” International Journal of Hypertension, vol. 2017, 10 pages, 2017.
[21] E. Gaviilikai, E. Gkaliagkousi, S. Grigoriadis, P. Anyfantí, S. Douma, and A. Anagnostopoulos, “Hypertension in hematologic malignancies and hematopoietic cell transplantation: an emerging issue with the introduction of novel treatments,” *Blood Reviews*, vol. 35, no. 35, pp. 51–58, 2019.

[22] R. Rani, V. Mengi, R. Kumar Gupta, and H. K. Sharma, “Hypertension and its risk factors-a cross sectional study in an urban population of a north Indian District,” *Public Health Research*, vol. 5, no. 3, pp. 67–72, 2015.

[23] J. L. Benham, J. E. Booth, R. J. Sigal, S. S. Daskalopoulou, A. A. Leung, and D. M. Rabi, “Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes,” *IJF Heart & Vascular*, vol. 33, article 100725, 2021.

[24] L. E. Kassel and L. E. Odum, “Our own worst enemy: pharmacologic mechanisms of hypertension,” *Advances in Chronic Kidney Disease*, vol. 22, no. 3, pp. 245–252, 2015.

[25] C. J. Lee and S. Park, “Hypertension and heart failure with preserved ejection fraction,” *Heart Failure Clinics*, vol. 17, no. 3, pp. 337–343, 2021.

[26] T. Grobosch, T. Binscheck, F. Martens, and D. Lampe, “Accidental intoxication with Veratrum album,” *Journal of Analytical Toxicology*, vol. 32, pp. 768–773, 2008.

[27] L. A. Magee and D. P. Vom, “The management of severe hypertension,” *Seminars in Perinatology*, vol. 33, no. 3, pp. 138–142, 2009.

[28] K. M. Mirabito Colafella, D. M. Bovée, and A. H. J. Danser, “The renin-angiotensin-aldosterone system and its therapeutic targets,” *Experimental Eye Research*, vol. 186, article 107680, 2019.

[29] M. T. Abdel Ghafar, “An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension,” *Steroids*, vol. 163, no. 163, article 108701, 2020.

[30] Y. Liu, J. Sun, L. Zhong et al., “Combination of a biopharmaceutic classification system and physiologically based pharmacokinetic models to predict absorption properties of baicalin in vitro and in vivo,” *Journal of Traditional Chinese Medical Sciences*, vol. 8, no. 3, pp. 238–247, 2021.

[31] Q. Abuhassan, I. Khadra, K. Pyper, P. Augustijns, J. Brouwers, and G. W. Halbert, “Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems,” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 170, pp. 160–169, 2022.

[32] K. Pathak and S. Raghuvanshi, “Oral bioavailability: issues and solutions via nanoformulations,” *Clinical Pharmacokinetics*, vol. 54, no. 4, pp. 325–357, 2015.

[33] M. Abdel, N. M. Zaki, S. Mansour, and A. S. Geneid, “Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres,” *European Journal of Pharmaceutical Sciences*, vol. 51, pp. 59–66, 2014.

[34] C. Pi, T. Feng, J. Liang et al., “Polymer blends used to develop felodipine-loaded hollow microspheres for improved oral bioavailability,” *International Journal of Biological Macromolecules*, vol. 112, pp. 1038–1047, 2018.

[35] Q. Fu, M. Ma, M. Li et al., “Improvement of oral bioavailability for nisoldipine using nanocrystals,” *Powder Technology*, vol. 305, no. 103, pp. 757–763, 2017.

[36] S. Subramanian, S. Amit Kumar, B. Aruchamy, A. Geeva Prasanth, A. Sathish Kumar, and S. B. Sai, “Preparation, characterization, and drug release behavior of nitrendipine encapsulated grafted copolymer microspheres,” *Mater Today Proc.*, vol. 33, pp. 2296–2300, 2020.

[37] N. Di Trani, H. C. Liu, R. Qi et al., “Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension,” *Nanomedicine: Nanotechnology, Biology and Medicine*, vol. 37, article 102417, 2021.

[38] Y. Weerapol, S. Limmatvapirat, C. Jansakul, H. Takeuchi, and P. Srimornsa, “Enhanced dissolution and oral bioavailability of nifedipine by spontaneous emulsifying powders: effect of solid carriers and dietary state,” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 91, pp. 25–34, 2015.

[39] Y. T. Goo, S. Y. Park, B. R. Chae et al., “Optimization of solid self-dispersing micelle for enhancing dissolution and oral bioavailability of valsartan using Box-Behnken design,” *International Journal of Pharmaceutics*, vol. 585, article 119483, 2020.

[40] K. Aboul Fotouh, A. A. Allam, M. El-Badry, and A. M. El-Sayed, “A self-nanoemulsifying dDrug delivery system for enhancing the oral bioavailability of candesartan cilexetil: ex vivo and in vivo evaluation,” *Journal of Pharmaceutical Sciences*, vol. 108, no. 11, pp. 3599–3608, 2019.

[41] S. Meruva, P. Thool, S. Shah et al., “Formulation and performance of Irbesartan nanocrystalline suspension and granulated or bead-layered dried powders – part I,” *International Journal of Pharmaceutics*, vol. 568, article 118189, 2019.

[42] C. Thapa, A. Ahad, M. Agil, S. S. Imam, and Y. Sultana, “Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box–Behnken design,” *Journal of Drug Delivery Science and Technology*, vol. 44, pp. 431–439, 2018.

[43] S. Si, H. Li, and X. Han, “Sustained release olmesartan medoxomil loaded PLGA nanoparticles with improved oral bioavailability to treat hypertension,” *Journal of Drug Delivery Science and Technology*, vol. 55, article 101422, 2020.

[44] A. Fayyaz, V. P. Ranta, E. Toropainen et al., “Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits,” *European Journal of Pharmaceutical Sciences*, vol. 155, article 105553, 2020.

[45] S. Naskar, S. Sharma, and K. Kuotsu, “A smart gelatin nanoparticle for delivery of metoprolol succinate: a strategy for enhancing the therapeutic efficacy by improving bioavailability,” *Journal of Drug Delivery Science and Technology*, vol. 53, no. July, article 101214, 2019.

[46] E. Bokri, H. Felfel, and S. Bahri, “Prediction of plasma concentrations using in silico modelling and simulation approach: case of Acebutolol,” *Pharmaceutiques Françaises*, vol. 79, no. 5, pp. 530–538, 2021.

[47] L. Mo, G. Lu, X. Ou, and D. Ouyang, “Formulation and development of novel control release transdermal patches of carvedilol to improve bioavailability for the treatment of heart failure,” *Saudi Journal of Biological Sciences*, vol. 29, no. 1, pp. 266–272, 2021.

[48] R. Antonio, V. Vargas, J. María, V. Millán, and E. Fajardo, “Endocrinología, diabetes y nutrición -angiotensin system : basic and clinical -a general perspective,” *mdocrinología, Diabetes y Nutrición*, vol. 69, no. 1, pp. 52–62, 2022.

[49] A. Khattab, M. Mohamed, and E. B. Basilious, “Design of self-nanoemulsifying system to enhance absorption and bioavailability of poorly permeable Aliskiren hemi-fumarate,”
Nanoemulsions: a novel drug delivery approach for pharmaceutical applications, *Journal of Drug Delivery Science and Technology*, vol. 57, article 101646, 2020.

G. Tiwari, R. Tiwari, S. Banneree et al., "Drug delivery systems: an updated review," *International Journal of Pharmaceutical Investigation*, vol. 2, no. 1, pp. 2–11, 2012.

A. Devaraj and G. Mahalingam, "Nanoemulsion formulation as an effective therapeutic drug delivery system in diabetes mellitus," in *Green Nanoparticles*, Nanotechnology in the Life Sciences, J. Patra, L. Fraceto, G. Das, and E. Campos, Eds., pp. 317–329, Springer, Cham, 2020.

T. H. Nikam, M. P. Patil, S. S. Patil, G. P. Vadhare, and S. Lodhi, "Nanoemulsion: a brief review on development and application in parenteral drug delivery," *Adv Pharm J.*, vol. 3, no. 2, pp. 43–54, 2018.

F. Laffleur and V. Keckes, "Advances in drug delivery systems: work in progress still needed?", *International Journal of Pharmaceutics*, vol. 590, no. 590, article 119912, 2020.

S. Kalepu and V. Nekkanti, "Insoluble drug delivery strategies: review of recent advances and business prospects," *Acta Pharmacutica Sinica B*, vol. 5, no. 5, pp. 442–453, 2015.

H. Zhu, J. Gao, L. Wang, K. J. Qian, and L. P. Cai, "In study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-kB signaling pathway," *Experimental and Therapeutic Medicine*, vol. 15, no. 3, pp. 2643–2648, 2018.

R. Pala, V. T. Anju, M. Dyavaiah, S. Busi, and S. M. Nauli, "Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases," *International Journal of Nanomedicine*, vol. 15, pp. 3741–3769, 2020.

Y. Deng, X. Zhang, H. Shen et al., "Application of the nano-drug delivery system in treatment of cardiovascular diseases," *Frontiers in Bioengineering and Biotechnology*, vol. 7, pp. 1–18, 2020.

N. A. Emad, B. Ahmed, A. Alhalmi, N. Alzubaidi, and S. S. Al-Kubati, "Recent progress in nanocarriers for direct nose to brain drug delivery," *Journal of Drug Delivery Science and Technology*, vol. 64, article 102642, 2021.

D. Julian, "Progress in lipid research advances in edible nanoemulsions: digestion, bioavailability, and potential toxicity," *Progress in Lipid Research*, vol. 81, article 101081, 2021.

M. Jaiswal, R. Dudhe, and P. K. Sharma, "Nanoemulsion: an advanced mode of drug delivery system," *J Biotech*, vol. 5, no. 2, pp. 123–127, 2015.

P. Pandey, N. Gulati, M. Makhija, D. Purohit, and H. Dureja, "Nanoemulsions: a novel drug delivery approach for enhancement of bioavailability," *Recent Patents on Nanotechnology*, vol. 14, no. 4, pp. 276–293, 2020.

M. Kumar, R. S. Bishnoi, A. K. Shukla, and C. P. Jain, "Techniques for formulation of nanoemulsion drug delivery system: a review," *Preventive Nutrition and Food Science*, vol. 24, no. 3, pp. 225–234, 2019.

A. Ali, V. A. Ansari, U. Ahmad, J. Akhtar, and A. Jahan, "Nanoemulsion: an advanced vehicle for efficient drug delivery," *Drug Research*, vol. 67, no. 11, pp. 617–631, 2017.

I. Capron, "Pickering nanoemulsions: an overview of manufacturing processes, formulations, and applications," *JCIS Open*, vol. 4, article 100036, 2021.

N. H. C. Marzuki, R. A. Wahab, and M. A. Hamid, "An overview of nanoemulsion: concepts of development and cosmeceutical applications," *Biotechnology and Biotechnological Equipment*, vol. 33, no. 1, pp. 779–797, 2019.

R. J. Wilson, Y. Li, G. Yang, and C.-X. Zhao, "Nanoemulsions for drug delivery," *Particuology*, vol. 64, pp. 85–97, 2022.

N. M. Aljabri, N. Shi, and A. Cavazos, "Nanoemulsion: an emerging technology for oilfield applications between limitations and potentials," *Journal of Petroleum Science and Engineering*, vol. 208, no. 208, article 109306, 2022.

S. Verma, Y. Vaishnav, S. K. Verma, and A. K. Jha, "Anhydrous nanoemulsions: an advanced drug delivery system for poorly aqueous soluble drugs," *Current Nanomedicine (Formerly: Recent Patents on Nanomedicine)*, vol. 7, no. 1, pp. 36–46, 2017.

V. Harshitha, M. V. Swamy, D. P. Kumar, K. S. Rani, and A. Trinath, "Nanoemulgel: a process promising in drug delivery system," *Research Journal of Pharmaceutical Dosage Forms and Technology*, vol. 12, no. 2, p. 125, 2020.

M. Sharma, R. Sharma, D. K. Jain, and A. Saraf, "Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: optimization and pharmacokinetic study," *International Journal of Biological Macromolecules*, vol. 135, no. 135, pp. 246–260, 2019.

N. Aminu, I. Bello, N. M. Umar, N. Tanko, A. Aminu, and M. M. Audu, "The influence of nanoparticulate drug delivery systems in drug therapy," *Journal of Drug Delivery Science and Technology*, vol. 60, article 101961, 2020.

M. R. Patel, R. B. Patel, and S. D. Thakore, "In applications of nanocomposite materials in drug delivery," in *Nanoemulsion in drug delivery*, Elsevier Inc, 2018.

T. Li, W. Liang, X. Xiao, and Y. Qian, "Nanochemistry, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases," *International Journal of Nanomedicine*, vol. 13, pp. 7349–7362, 2018.

B. Homayun, X. Lin, and H. J. Choi, "Challenges and recent progress in oral drug delivery systems for biopharmaceuticals," *Pharmaceutics*, vol. 11, no. 3, p. 129, 2019.

D. Julian, "Advances in edible nanoemulsions: digestion, bioavailability, and potential toxicity," *Progress in Lipid Research*, vol. 2021, no. 81, article 101081, 2020.

R. Kumar and A. Dabás, "Bioavailability of nanoemulsion formulations vs conventional fat soluble preparations of cholecalciferol (D3) - an overview," *J Clin Orthop Trauma.*, vol. 10, no. 6, pp. 1094–1096, 2019.

N. Kommana, K. Bharti, D. B. Surekha, S. Thokala, and B. Mishra, "Development, optimization and evaluation of losartan potassium loaded self emulsifying drug delivery system," *J Drug Deliv Sci Technol.*, vol. 60, article 102026, 2020.

R. J. Patel and R. H. Parikh, "Intranasal delivery of topiramate nanoemulsion: pharmacodynamic, pharmacokinetic and brain uptake studies," *International Journal of Pharmaceutics*, vol. 585, article 119486, 2020.

Y. Nakano, M. Tajima, E. Sugiyama, V. H. Sato, and H. Sato, "Development of a novel nano-emulsion formulation to improve intestinal absorption of cannabidiol," *Med Cannabis Cannabinoids*, vol. 2, no. 1, pp. 35–42, 2019.

R. Zhang and D. J. McElderry, "Characterization of gastrointestinal fate of nanoemulsions," in *Nanoemulsions*, pp. 577–612, Elsevier Inc, 2018.

R. Zhang, Z. Zhang, and D. Julian, "Nanoemulsions: an emerging platform for increasing the efficacy of nutraceuticals in foods," *Colloids Surfaces B Biointerfaces*, vol. 194, no. June, article 111202, 2020.
[82] C. Zhao, L. Wei, B. Yin et al., "Encapsulation of lycopene within oil-in-water nanoemulsions using lactoferrin: impact of carrier oils on physicochemical stability and bioaccessibility," *International Journal of Biological Macromolecules*, vol. 153, pp. 912–920, 2020.

[83] Z. Niu, A. Acevedo-fani, A. Mcdowell, A. Barnett, S. M. Lovey, and H. Singh, "Nanoemulsion structure and food matrix determine the gastrointestinal fate and in vivo bioavailability of coenzyme Q10," *Journal of Controlled Release*, vol. 327, no. August, pp. 444–455, 2020.

[84] M. Yao, Z. Li, D. Julian, Z. Tang, and H. Xiao, "Design of nanoemulsion-based delivery systems to enhance intestinal lymphatic transport of lipophilic food bioactives: in vivo elution of oil type," *Food Chemistry*, vol. 317, article 126229, 2020.

[85] Y. Singh, J. G. Meher, K. Raval et al., "Nanoemulsion: concepts, development and applications in drug delivery," *Journal of Controlled Release*, vol. 252, pp. 28–49, 2017.

[86] D. Babadi, S. Dadashzadeh, M. Osouli, M. S. Daryabari, and A. Haeri, "Nanoformulation strategies for improving intestinal permeability of drugs: a more precise look at permeability assessment methods and pharmacokinetic properties changes," *Journal of Controlled Release*, vol. 321, pp. 669–709, 2020.

[87] N. Vishwakarma, A. Jain, R. Sharma, N. Mody, S. Vyas, and S. P. Vyas, "Lipid-based nanoformulations for lymphatic transport," *AAPS Pharm Sci Tech*, vol. 20, no. 2, pp. 1–13, 2019.

[88] N. Hanifah, Y. F. Achmad, A. Humaira, and S. I. O. Salasia, "Red ginger-extract nanoemulsion modulates high blood pressure in rats by regulating angiotensin-converting enzyme production," *Vet World*, vol. 14, no. 1, pp. 176–181, 2021.

[89] V. P. Mundada, M. H. Patel, P. K. Mundada, and K. K. Sawant, "Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies," *Drug Development and Industrial Pharmacy*, vol. 46, no. 3, pp. 376–387, 2020.

[90] R. Jain and V. B. Patravale, "Development and evaluation of nitrendipine nanoemulsion for intranasal delivery," *Journal of Biomedical Nanotechnology*, vol. 5, no. 1, pp. 62–68, 2009.

[91] S. Singh, T. Virmani, and K. Kohli, "Nanoemulsion system for improvement of raspberry ketone oral bioavailability," *Indo Glob J Pharm Sci*, vol. 10, no. 1, pp. 33–42, 2020.

[92] A. Khames, "Formulation and characterization of eplerenone nanoemulsion liquisolids, an oral delivery system with higher release rate and improved bioavailability," *Pharmaceutics*, vol. 11, no. 1, p. 40, 2019.

[93] S. Khani, F. Keyhanfar, and A. Amani, "Design and evaluation of oral nanoemulsion drug delivery system of mebubipine," *Drug Delivery*, vol. 23, no. 6, pp. 2035–2043, 2016.

[94] B. Gorain, H. Choudhury, A. Kundu et al., "Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats," *Colloids Surfaces B Biointerfaces*, vol. 1, no. 115, pp. 286–294, 2014.

[95] S. Shafiq, F. Shakeel, S. Talegaonkar, F. J. Ahmad, R. K. Khar, and M. Ali, "Development and bioavailability assessment of ramipril nanoemulsion formulation," *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 66, no. 2, pp. 227–243, 2007.

[96] H. H. Ali and A. A. Hussein, "Oral nanoemulsions of candesartan cilexetil: formulation, characterization and in vitro drug release studies," *AAPS Open*, vol. 3, no. 1, 2017.

[97] R. Abu-Huwaij, R. Hamed, E. Daoud, and A. Z. Alkilani, "Development and in vitro characterization of nanoemulsion-based buccal patches of valsartan," *Acta Poloniae Pharmaceutica-Drug Research*, vol. 76, no. 2, pp. 313–321, 2019.

[98] G. Chhabra, K. Chuttani, A. K. Mishra, and K. Pathak, "Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability," *Drug Development and Industrial Pharmacy*, vol. 37, no. 8, pp. 907–916, 2011.

[99] R. Kumar, G. C. Soni, and S. K. Prajapati, "Formulation development and evaluation of telmisartan nanoemulsion," *International Journal of Research and Development in Pharmacy & Life Sciences*, vol. 6, no. 4, pp. 2711–2719, 2017.

[100] M. Rizwan, M. Aqil, A. Azeem, S. Talegaonkar, Y. Sultana, and A. Ali, "Enhanced transdermal delivery of carvedilol using nanoemulsion as a vehicle," *Journal of Experimental Nanoscience*, vol. 5, no. 5, pp. 390–411, 2010.

[101] J. Varshosaz, S. Andalib, M. Tabhakhian, and N. Ebrahimzadeh, "Development of lecithin nanoemulsion based organogels for permeation enhancement of metoprolol through rat skin," *Journal of Nanomaterials*, vol. 2013, 10 pages, 2013.

[102] D. Ghai and V. R. Sinha, "Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoreceptor blocker Talinolol," *Nanomedicine: Nanotechnology, Biology and Medicine*, vol. 8, no. 5, pp. 618–626, 2012.

[103] S. Mishra, "Determining patent filing targets based on patent cost retrieval from Patent Examination Data System," *World Patent Information*, vol. 65, article 102024, 2021.

[104] A. Naseema, L. Kovooru, A. K. Behera, K. P. P. Kumar, and P. Srivastava, "A critical review of synthesis procedures, applications and future potential of nanoemulsions," *Advances in Colloid and Interface Science*, vol. 287, article 102318, 2021.